Alexion, AstraZeneca Rare Disease
Alexion is a global biopharmaceutical company that focuses on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes the first and only approved complement inhibitor to treat patients with PNH and aHUS. In addition, Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies.